New cocktail of chemo and immunotherapy aims to fight advanced ovarian cancer

NCT ID NCT05952453

Recruiting now Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This phase 2 trial is testing a combination of three drugs (carboplatin, paclitaxel, and pembrolizumab) given before surgery to shrink tumors in women with newly diagnosed stage III or IV ovarian cancer. After surgery, participants receive two maintenance drugs (olaparib and pembrolizumab) to help keep the cancer from coming back. The study will track how long the cancer stays under control, with 20 participants expected to enroll.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carboplatin, paclitaxel, pembrolizumab, olaparib
What this could lead to: If successful, this could improve how long advanced ovarian cancer stays under control after initial treatment.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The combination of drugs may cause side effects, and the benefit over standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

O'Neal Comprehensive Cancer Center at UAB
RECRUITING

Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.